Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Analyst picks & changes

Immunex Corp. (IMNX)

Bruce Schackman of Furman Selz removed IMNX from the firm's Recommended List. The announcement that majority shareholder American

Read the full 218 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE